Pulsenmore Announces Full Year 2025 Financial Results and Webcast

Rhea-AI Summary

Pulsenmore (NASDAQ: PLSM) reported full-year 2025 revenue of $12.5 million, a 374% increase versus 2024, driven largely by a $9.6 million one-time settlement with GE. Net loss improved to $5.0 million from $10.0 million in 2024. Total liquid assets were $21.7 million (including $7.0 million cash) as of Dec 31, 2025.

Key operational milestones include FDA clearance for remote-use prenatal ultrasound in the U.S., MDR/CE certification for the Pulsenmore Early-Screening pregnancy product in Europe, and initial U.S. commercial programs. Management will host a webcast today, March 30, 2026, at 8:30am ET to discuss results and business update.

Positive

• Revenue +374% to $12.5M in 2025 (includes $9.6M GE settlement)
• Gross margin approximately 84% in 2025
• Net loss improved 50% to $5.0M year-over-year
• Received FDA clearance for remote-use prenatal ultrasound in the U.S.
• Obtained MDR/CE certification for Pulsenmore Early-Screening in EU
• Total liquid assets of $21.7M as of December 31, 2025

Negative

• Revenue included a non-recurring $9.6M settlement from GE, reducing recurring revenue visibility
• Operating expenses increased to $14.4M in 2025 from $12.6M in 2024
• Cash and cash equivalents of $7.0M may constrain near-term liquidity

Market Context

This announcement highlights strong 2025 revenue growth to $12.5 million, a materially lower net los...

Analysis

This announcement highlights strong 2025 revenue growth to $12.5 million, a materially lower net loss of $5 million, and a high reported gross margin of 84%, aided by a one-time $9.6 million GE settlement. It also underscores recent FDA and European regulatory clearances and initial U.S. commercial deployments. Investors may watch how core revenues evolve without one-time items, the pace of U.S. uptake, and changes in operating expenses from the $14.4 million 2025 level.

Key Figures

2025 Revenue: $12.5 million Revenue Growth: 374% GE Settlement Revenue: $9.6 million +5 more

8 metrics

2025 Revenue $12.5 million Full year 2025, vs approximately $2.6 million in 2024

Revenue Growth 374% Increase in 2025 revenue compared to 2024

GE Settlement Revenue $9.6 million One-time revenue contribution related to GE settlement in 2025

Net Loss 2025 $5 million Net loss for 2025, improved from $10 million in 2024

Total Liquid Assets $21.7 million As of December 31, 2025, including $7 million in cash and equivalents

Cost of Revenues 2025 $2.0 million Full year 2025, compared to $1.7 million in 2024

Gross Profit 2025 $10.5 million Full year 2025, vs $0.98 million in 2024 (gross margin 84% vs 37%)

Operating Expenses 2025 $14.4 million Full year 2025, compared to $12.6 million in 2024

Historical Context

4 past events · Latest: Mar 25 (Neutral)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 25	Earnings call notice	Neutral	-5.5%	Announcement of timing and speakers for full-year 2025 earnings call.
Feb 09	Commercial agreement	Positive	+0.9%	U.S. commercial services agreement to integrate home ultrasound in prenatal care.
Feb 02	First U.S. engagement	Positive	+4.8%	First U.S. commercial agreement for Pulsenmore ES home pregnancy ultrasound services.
Jan 26	Strategic agreement	Positive	+3.9%	Strategic deal with Clalit for at-home follicular monitoring service with multiyear value.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamentally positive commercial and partnership updates have mostly seen aligned positive price reactions, with one divergence on an earnings call notice.

Recent Company History

Over the last few months, Pulsenmore has reported several commercial and regulatory milestones. On Jan 26, 2026, it announced a strategic agreement with Clalit for at‑home follicular monitoring, followed by its first U.S. commercial engagement on Feb 2, 2026 and another U.S. agreement on Feb 9, 2026. These updates saw mostly positive price reactions. The Mar 25, 2026 earnings call notice drew a negative move. Today’s full‑year 2025 results add detailed financials and context after that earlier call announcement.

Key Terms

fda clearance, de novo authorization, medical device regulation (mdr), conformité européenne (ce) certification, +1 more

5 terms

fda clearance regulatory

"Regulatory milestone – U.S.: Secured FDA clearance for remote-use prenatal ultrasound"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

de novo authorization regulatory

"Following our FDA De Novo authorization and Nasdaq listing, we focused on scaling"

A de novo authorization is a regulatory pathway the U.S. Food and Drug Administration for approving a novel medical device that has no previously cleared “predicate” device and is judged to pose low-to-moderate risk. For investors, it matters because it can allow a company to bring a new product to market faster and with lower cost and regulatory burden than the most stringent approval routes, potentially speeding revenue, improving valuation prospects, and establishing an early competitive foothold.

medical device regulation (mdr) regulatory

"Received Medical Device Regulation (MDR) Conformité Européenne (CE) Certification"

Medical device regulation (MDR) sets the safety, performance and marketing rules manufacturers must meet before medical devices can be sold or used. Think of it like building codes and inspections for products that touch people’s health: meeting MDR standards affects how quickly a device reaches patients, how much it costs to bring to market, and the legal or recall risks investors should weigh when valuing companies in the sector.

conformité européenne (ce) certification regulatory

"Received Medical Device Regulation (MDR) Conformité Européenne (CE) Certification"

A CE (Conformité Européenne) certification is a manufacturer’s mark showing a product meets European safety, health and environmental rules and is allowed to be sold across the EU market. For investors, it’s a practical green light: it reduces regulatory and legal risk, affects how easily a product can reach millions of customers, and can change production costs or liability exposure—like a vehicle passing a safety inspection before it can drive on public roads.

form 20-f regulatory

"A copy of Pulsenmore's annual report on Form 20-F for the year ended"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Management to Host Conference Call and Webcast today at 8:30am ET to Discuss Results and Provide Business Update

OMER, Israel, March 30, 2026  /PRNewswire/ – Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced financial results for the full year ended December 31, 2025.

 

 

Full-Year 2025 Financial Highlights

• Full year revenue of $12.5 million, representing a 374% increase compared to 2024, including a one-time revenue contribution of $9.6 million related to the GE settlement discussed below.
• Net loss improved significantly to $5 million, compared to $10 million in 2024.
• $21.7 million in total liquid assets (including $7 million in cash and cash equivalents) as of December 31, 2025.
• Recognized approximately $9.6 million in one-time revenue in connection with a settlement agreement with GE Precision Healthcare LLC (GEHC), which resolved all outstanding disputes between the parties and concluded all related proceedings. Approximately $2.2 million was recognized as revenue from the cancellation of orders placed by GEHC for 15,000 units pursuant to the Settlement Agreement and the termination of the Component Agreement.

Operational Highlights

• Regulatory milestone – U.S.: Secured FDA clearance for remote-use prenatal ultrasound in the United States, establishing the regulatory foundation for entry into the world's largest prenatal diagnostics market.
• Regulatory milestone – Europe: Received Medical Device Regulation (MDR) Conformité Européenne (CE) Certification for the Pulsenmore Early-Screening (ES) pregnancy product, authorizing commercial distribution across the European Union for single-fetus pregnancies starting at 14 weeks of gestation.
• Commercial milestone: Initial U.S. commercial programs validating Pulsenmore ES home-use ultrasound integration with clinical workflows ahead of broader rollout.

"2025 was a transformative year for Pulsenmore as we advanced from regulatory achievement to commercial execution," said Dr. Elazar Sonnenschein, CEO and Founder of Pulsenmore. "Following our FDA De Novo authorization and Nasdaq listing, we focused on scaling our U.S. infrastructure, expanding clinical partnerships, and strengthening our operational capabilities to support long-term growth.

We are seeing encouraging validation from providers and health systems who recognize the value of remote, clinician-directed ultrasound as part of modern prenatal care. As we enter 2026, our focus remains on accelerating commercial momentum, increasing utilization, strengthening recurring revenue streams while maintaining disciplined investment. We believe the progress achieved in 2025 positions Pulsenmore to execute on a significant market opportunity in remote prenatal diagnostics."

Financial Highlights for Full Year Ended December 31, 2025 Revenues for the year ended December 31, 2025 were $12.5 million, compared to approximately $2.6 million for the year ended December 31, 2024. Revenues were primarily contributed by a $9.6 million one-time payment related to the GE settlement.

Cost of Revenues was $2.0 million for the year ended December 31, 2025, compared to $1.7 million for the year ended December 31, 2024. The increase primarily reflects higher revenues from both core operations and the one-time settlement, partially offset by improved operational efficiency.

Gross Profit was $10.5 million for the year ended December 31, 2025, compared to gross profit of $0.98 million for the year ended December 31, 2024, reflecting a gross margin of approximately 84% in 2025, up from 37% in 2024.

Operating expenses were $14.4 million for the year ended December 31, 2025, compared to $12.6 million for the year ended December 31, 2024. The increase was primarily driven by investments in scaling U.S. infrastructure, expanding clinical partnerships, and strengthening operational capabilities.

Net loss was $5 million for the year ended December 31, 2025, compared to $10 million for the year ended December 31, 2024, representing a 50% improvement year-over-year.

Total liquid assets as of December 31, 2025 was approximately $21.7 million.

Webcast Details

Pulsenmore will host a webcast to review the full year 2025 results today on March 30th at 8:30 am Eastern Time / 3:30 p.m. Israel Time.

Webcast: https://teams.microsoft.com/meet/3845461353556?p=fcIpXc4mErwEAqo3Ir

Replay: The meeting will be recorded, and the recording will be made available following the meeting on the Company's Investor Relations website at: https://pulsenmore.com/investor_relations

A copy of Pulsenmore's annual report on Form 20-F for the year ended December 31, 2025 has been filed with the U.S. Securities and Exchange Commission at https://www.sec.gov/ and posted on Pulsenmore's investor relations website at https://pulsenmore.com/investor_relations/. Pulsenmore will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request at msegal@ms-ir.com.

About Pulsenmore
Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com

This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to Pulsenmore's continued commercial momentum, clinician adoption expansion, strengthening its presence in the U.S. market following its Nasdaq listing and FDA De Novo authorization, accelerating commercial momentum, increasing utilization, strengthening recurring revenue streams while maintaining disciplined investment and its belief that the progress achieved in 2025 positions it to execute on a significant market opportunity in remote prenatal diagnostics. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and in subsequent filings with the SEC. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

Investor Contact:
Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com

 

PULSENMORE LTD.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
		December 31,
		2024		2025		2025
		NIS in thousands			USD in thousands
Assets
CURRENT ASSETS
Cash and cash equivalents		41,170		21,604		6,773
Short-term bank deposits		62,853		47,531		14,900
Restricted deposits		140		140		44
Trade receivables		3,909		4,144		1,300
Other receivables		1,237		1,391		436
Inventory – current portion		23,092		6,593		2,067
Total current assets		132,401		81,403		25,520
NON-CURRENT ASSETS
Inventory – non-current portion		-		13,337		4,181
Right-of-use assets		1,780		1,285		403
Property and equipment, net		7,645		5,822		1,825
Total non-current assets		9,425		20,444		6,409
Total assets		141,826		101,847		31,929
Liabilities and equity
CURRENT LIABILITIES
Trade payables		2,359		1,980		621
Other payables and accruals		3,780		4,407		1,382
Contract liabilities		5,133		938		294
Share-based compensation liability		1,458		276		87
Current maturities of liability for royalties to the Israel Innovation Authority		532		1,705		534
Current maturities of lease liabilities		999		1,023		321
Total current liabilities		14,261		10,329		3,239
NON-CURRENT LIABILITIES
Contract liabilities		22,897		-		-
Share-based compensation liability, net of current maturities		164		-		-
Liability for royalties to the Israel Innovation Authority, net of current maturities		6,497		7,886		2,472
Lease liabilities, net of current maturities		1,120		542		170
Total non-current liabilities		30,678		8,428		2,642
Total liabilities		44,939		18,757		5,881
EQUITY
Ordinary shares		2		2		1
Share premium		253,205		256,137		80,294
Capital reserve		10,968		10,092		3,164
Accumulated deficit		(167,288)		(183,141)		(57,411)
Total equity		96,887		83,090		26,048
Total liabilities and equity		141,826		101,847		31,929
All share and per share amounts have been retroactively adjusted to reflect a 1-for-8 reverse share split as discussed in Note 1(b)
The accompanying notes are an integral part of the consolidated financial statements.

 

PULSENMORE LTD.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
		December 31,
		2024		2025		2025
		NIS in thousands			USD in thousands
Revenues		9,661		9,484		2,973
Revenues from settlement agreement with GEHC (*)		-		30,540		9,574
Total revenues		9,661		40,024		12,547
Cost of revenues		6,084		6,342		1,988
Gross profit		3,577		33,682		10,559
Research and development expenses, net		20,130		17,350		5,439
Sales and marketing expenses		10,318		11,815		3,704
General and administrative expenses		15,344		16,681		5,230
Operating loss		42,215		12,164		3,814
Financial expenses		540		7,225		2,265
Financial income		(5,963)		(3,537)		(1,109)
Financial expenses (income), net		(5,423)		3,688		1,156
Loss before income tax		36,792		15,852		4,970
Provision (benefit) for income tax		(56)		1		**
Net loss and comprehensive loss		36,736		15,853		4,970
Loss per ordinary share – basic and diluted		5.76		2.46		0.77
* Including an amount of NIS 7.1 million (approximately $2.2 million) was recognized as revenues from the (1) cancellation of orders placed by GEHC to the Company for 15,000 units Pursuant to the Settlement Agreement and (2) due to the termination of the Component Agreement.
** Less than $1 thousand

 

Logo: https://mma.prnewswire.com/media/2942134/Pulsenmore_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/pulsenmore-announces-full-year-2025-financial-results-and-webcast-302728608.html

SOURCE Pulsenmore Ltd.

FAQ

What drove Pulsenmore's reported 2025 revenue of $12.5M (PLSM)?

The revenue increase was largely due to a one-time $9.6M settlement with GE. According to the company, the settlement resolved outstanding disputes and contributed approximately $9.6M to 2025 revenue, while core operational sales accounted for the remainder of the $12.5M total.

How did Pulsenmore's net loss change in full-year 2025 for PLSM shareholders?

Net loss improved to $5.0M in 2025, down from $10.0M in 2024. According to the company, the improvement reflects higher revenue including the GE settlement and operational efficiencies, partially offset by increased investments to scale U.S. infrastructure and partnerships.

What regulatory milestones did Pulsenmore announce in 2025 for PLSM products?

Pulsenmore secured FDA clearance in the U.S. and MDR/CE certification in Europe for its pregnancy product. According to the company, FDA De Novo authorization enables remote-use prenatal ultrasound and CE certification permits EU commercial distribution for single-fetus pregnancies from 14 weeks.

How much cash and liquid assets did Pulsenmore report as of December 31, 2025 (PLSM)?

Pulsenmore reported approximately $21.7M in total liquid assets, including $7.0M in cash and cash equivalents. According to the company, this liquidity position reflects the year-end balance available to support ongoing commercialization and operational investments.

When is Pulsenmore's webcast to discuss full-year 2025 results and how can investors access it (PLSM)?

The company will host a webcast on March 30, 2026 at 8:30am ET to review results and provide a business update. According to the company, the live webcast link is available through its investor relations site and a replay will be posted after the meeting.